Hospital policy of tranexamic acid to reduce transfusion in major noncardiac surgery (Registro nro. 22761)

000 -Cabecera
Campo de control interno 03033nam a2200289 4500
001 - Número de control
control field ESSALUD
005 - Fecha y hora de la última transacción
Campo de control 20260805000231.0
007 - Tipo material - Descripcion fisica - info general
Tipo material - Descripcion fisica - info general ta
008 - Elementos de Longitud Fija - Información General
Elementos de Longitud Fija - Información t pe ||||| |||| 00| 0 spa d
040 ## - Origen de la Catalogación
Origen de la Catalogación BMG
041 ## - Idioma
Idioma eng
100 ## - Autor
Autor Houston, Brett L.
Rol del Autor Autor
9 (RLIN) 53871
245 ## - Titulo
Titulo Hospital policy of tranexamic acid to reduce transfusion in major noncardiac surgery
300 ## - Páginas
Paginación páginas: 2419-2428
520 ## - Resumen
Resumen Background: Whether a hospital policy of tranexamic acid administration for patients undergoing major noncardiac surgery safely reduces the need for red-cell transfusion is uncertain.<br/>Methods: We conducted a multicenter, double-blind, cluster-randomized, placebo-controlled trial involving patients undergoing noncardiac surgery who were at high risk for red-cell transfusion. Hospitals were randomly assigned at 4-week intervals to a hospital-wide policy of intraoperative tranexamic acid or placebo. The coprimary effectiveness and safety outcomes were transfusion of red cells during the index hospitalization and diagnosis of venous thromboembolism within 90 days, respectively. The safety outcome was assessed for noninferiority, with a prespecified noninferiority margin defined as an upper boundary of 1.46 for the 95% confidence interval of the relative risk. Analyses used mixed-effects models that accounted for the cluster-crossover design. Results: A total of 8273 patients enrolled across 10 Canadian hospitals could be evaluated for the coprimary outcomes. Oncologic surgery accounted for 60.5% of the surgical procedures (5002 of 8273). The percentage of patients who received a red-cell transfusion during hospitalization was 7.4% (306 of 4156) in the tranexamic acid group and 9.8% (403 of 4117) in the placebo group (relative risk, 0.73; 95% confidence interval [CI], 0.61 to 0.86; adjusted difference, −2.7 percentage points; 95% CI, −4.2 to −1.4). Venous thromboembolism within 90 days occurred in 2.1% of patients (86 of 4128) in the tranexamic acid group and 2.1% of patients (85 of 4052) in the placebo group (relative risk, 0.96; 95% CI, 0.65 to 1.38; adjusted difference, −0.1 percentage points; 95% CI, −0.9 to 0.7), which met the criterion for noninferiority. Conclusions: <br/>Among patients undergoing major noncardiac surgery, a hospital policy of tranexamic acid administration resulted in a lower incidence of red-cell transfusion than placebo administration, and tranexamic acid was noninferior to placebo with regard to diagnosis of venous thromboembolism.
650 ## - Temas - Descriptores
Temas - Descriptores ANTICOAGULACIÓN
9 (RLIN) 53834
650 ## - Temas - Descriptores
Temas - Descriptores TROMBOEMBOLISMO
9 (RLIN) 32218
650 ## - Temas - Descriptores
Temas - Descriptores CARDIOLOGÍA
9 (RLIN) 11301
650 ## - Temas - Descriptores
Temas - Descriptores NEUMOLOGÍA
9 (RLIN) 25628
700 ## - Autor Personal
Autor Personal McIsaac, Daniel I.
9 (RLIN) 53872
700 ## - Autor Personal
Autor Personal Breau, Rodney H.
9 (RLIN) 53873
700 ## - Autor Personal
Autor Personal Kanji, Salmaan
9 (RLIN) 53874
700 ## - Autor Personal
Autor Personal Greenstreet, Peter
9 (RLIN) 53875
700 ## - Autor Personal
Autor Personal Andrews, Meghan
9 (RLIN) 53876
773 0# - Revista (Relacion con el numero)
Host Biblionumber 22717
Host Itemnumber 22639
Ciudad, Editorial Massachusetts NEJM Group
Codigo barras item/ejemplar NEJM006
Titulo de la Revista The New England Journal of Medicine
Número de control de registro ESSALUD
ISSN 0028-4793
942 ## - Elementos de Koha
Tipo de Documento Artículos
Fecha procesamiento 2026-07-31
Catalogador SQB

No hay ítems disponibles.